Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

8th World Congress on Virology

San Antonio, USA

Maduike C.O. Ezeibe

Maduike C.O. Ezeibe

Michael Okpara University of Agriculture, Nigeria

Title: Clinical trial of Medicinal synthetic Aluminum-magnesium silicate (Antivirt®) on CD4-Lymphocytes counts and viral loads of HIV/AIDS patients

Biography

Biography: Maduike C.O. Ezeibe

Abstract

Molecules of Aluminum-magnesium silicate (AMS) are made of Nanoparticles which have negative electrical charges on their surfaces and positive charges on their edges while HIV has positive electrical charges. Abnormal cells are negatively charged. AMS Nanoparticles therefore, interfere with attachment of HIV to cells of its hosts by electrostatic bonds between their negatively  charged  surfaces and positive charges on the virus, thus inhibiting the viral replication and mopping out its particles.  The Nanoparticles also adsorb onto HIV-infected cells by attraction between their positively charged edges and negative charges on the abnormal cells. Such cells are destroyed by same mechanism AMS traditionally disintegrates drug-capsules. For clinical trial of antiretroviral effects of the Medicinal synthetic Aluminum-magnesium silicate (Antivirt®) on viral loads and CD4-lymphocytes counts, 10 HIV/AIDS patients were treated. Their blood samples were tested for viral loads and CD4-lymphocytes counts, before treatment and every 4 weeks. The regime was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin trihydrate (7.5 mg/kg) and immune stimulants, for 4 weeks. Then, it was reduced to, only 50 mg/kg (MSAMS) and immune stimulants.  If a patient`s viral load reduced to zero, the treatment would continue for another 4 weeks. Results so far, show that mean CD4-lymphocytes counts of the patients reduced (P =0.008) initially, from 496.80±194.39 to 263.90±149.26 after 4 weeks and then improved (P=0.001), to 507.90±133.19, after 8 weeks. Also, their mean viral load increased (P=0.020) initially, from 1,820.30 ± 868.75 to 2,855.90±960.98 after 4 weeks and then reduced (P= 0.030) to 1,565.20±743.17, after 8 weeks. It has therefore been concluded that: by destroying HIV-infected cells to unmask “hidden infections”; by having access to all organs/tissues (as Nanoparticles); by continually mopping HIV out from organs/tissues; by enhancing effective treatment of secondary infections and by encouraging better immune response in  patients, the Antivirt® -therapy  may lead to cure for HIV/AIDS